Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.87
BIO's Cash to Debt is ranked lower than
52% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. BIO: 1.87 )
Ranked among companies with meaningful Cash to Debt only.
BIO' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.81 Max: 1.87
Current: 1.87
0.04
1.87
Equity to Asset 0.67
BIO's Equity to Asset is ranked higher than
64% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIO: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
BIO' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.53 Max: 0.68
Current: 0.67
0.33
0.68
Interest Coverage 5.94
BIO's Interest Coverage is ranked lower than
78% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. BIO: 5.94 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s Interest Coverage Range Over the Past 10 Years
Min: 2.77  Med: 5.04 Max: 7.69
Current: 5.94
2.77
7.69
F-Score: 5
Z-Score: 4.03
M-Score: -2.44
WACC vs ROIC
7.43%
4.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.57
BIO's Operating margin (%) is ranked higher than
61% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.14 vs. BIO: 6.57 )
Ranked among companies with meaningful Operating margin (%) only.
BIO' s Operating margin (%) Range Over the Past 10 Years
Min: 6.57  Med: 10.92 Max: 14.74
Current: 6.57
6.57
14.74
Net-margin (%) 4.75
BIO's Net-margin (%) is ranked higher than
63% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. BIO: 4.75 )
Ranked among companies with meaningful Net-margin (%) only.
BIO' s Net-margin (%) Range Over the Past 10 Years
Min: 3.65  Med: 7.18 Max: 9.63
Current: 4.75
3.65
9.63
ROE (%) 3.84
BIO's ROE (%) is ranked higher than
59% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. BIO: 3.84 )
Ranked among companies with meaningful ROE (%) only.
BIO' s ROE (%) Range Over the Past 10 Years
Min: 3.7  Med: 9.64 Max: 13.98
Current: 3.84
3.7
13.98
ROA (%) 2.58
BIO's ROA (%) is ranked higher than
62% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.98 vs. BIO: 2.58 )
Ranked among companies with meaningful ROA (%) only.
BIO' s ROA (%) Range Over the Past 10 Years
Min: 2.28  Med: 5.14 Max: 6.83
Current: 2.58
2.28
6.83
ROC (Joel Greenblatt) (%) 14.14
BIO's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.85 vs. BIO: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 14.14  Med: 28.07 Max: 36.51
Current: 14.14
14.14
36.51
Revenue Growth (3Y)(%) -1.70
BIO's Revenue Growth (3Y)(%) is ranked lower than
61% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. BIO: -1.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.7  Med: 8.6 Max: 21
Current: -1.7
-1.7
21
EBITDA Growth (3Y)(%) -10.80
BIO's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. BIO: -10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.9  Med: 11 Max: 40.2
Current: -10.8
-10.9
40.2
EPS Growth (3Y)(%) -12.70
BIO's EPS Growth (3Y)(%) is ranked lower than
63% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. BIO: -12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.8  Med: 10.7 Max: 76.3
Current: -12.7
-25.8
76.3
» BIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BIO Guru Trades in Q4 2015

Paul Tudor Jones 3,600 sh (+4.53%)
Pioneer Investments 16,639 sh (+2.68%)
John Rogers 1,005,947 sh (+0.58%)
Ray Dalio Sold Out
First Pacific Advisors Sold Out
George Soros Sold Out
Ken Fisher 274,634 sh (-0.32%)
Mario Gabelli 67,000 sh (-1.76%)
Private Capital 14,402 sh (-1.87%)
NWQ Managers 425,876 sh (-4.00%)
Jim Simons 81,500 sh (-8.96%)
Steven Cohen 58,800 sh (-20.22%)
Joel Greenblatt 91,287 sh (-21.15%)
Chuck Royce 215,930 sh (-33.33%)
» More
Q1 2016

BIO Guru Trades in Q1 2016

Jim Simons 144,900 sh (+77.79%)
Private Capital Sold Out
Steven Cohen Sold Out
John Rogers 1,004,492 sh (-0.14%)
Mario Gabelli 66,500 sh (-0.75%)
NWQ Managers 422,546 sh (-0.78%)
Ken Fisher 269,075 sh (-2.02%)
Pioneer Investments 16,205 sh (-2.61%)
Paul Tudor Jones 3,335 sh (-7.36%)
Chuck Royce 192,930 sh (-10.65%)
Joel Greenblatt 67,705 sh (-25.83%)
» More
Q2 2016

BIO Guru Trades in Q2 2016

Mariko Gordon 20,392 sh (New)
Steven Cohen 38,800 sh (New)
NWQ Managers 503,466 sh (+19.15%)
Ken Fisher 281,583 sh (+4.65%)
Pioneer Investments 16,205 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
John Rogers 980,851 sh (-2.35%)
Mario Gabelli 63,200 sh (-4.96%)
Chuck Royce 178,630 sh (-7.41%)
Jim Simons 47,100 sh (-67.49%)
» More
Q3 2016

BIO Guru Trades in Q3 2016

Paul Tudor Jones 4,484 sh (New)
Ken Fisher 290,416 sh (+3.14%)
Steven Cohen 38,300 sh (-1.29%)
John Rogers 958,046 sh (-2.33%)
Mario Gabelli 61,112 sh (-3.30%)
Mariko Gordon 19,217 sh (-5.76%)
NWQ Managers 470,577 sh (-6.53%)
Jim Simons 43,000 sh (-8.70%)
Chuck Royce 150,030 sh (-16.01%)
Pioneer Investments 5,009 sh (-69.09%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:PKI, OTCPK:BMXMF, NAS:ICLR, NAS:DXCM, NAS:CPHD, NAS:QGEN, NAS:BRKR, NAS:VWR, NYSE:CRL, NYSE:ALR, NAS:PRAH, NAS:PRXL, OTCPK:ERFSF, NAS:INCR, OTCPK:CZMWY, NAS:NEOG, NAS:EXAS, NAS:MEDP, NAS:AXDX, NAS:ABAX » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Ratios

vs
industry
vs
history
P/E(ttm) 53.28
BIO's P/E(ttm) is ranked lower than
78% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.96 vs. BIO: 53.28 )
Ranked among companies with meaningful P/E(ttm) only.
BIO' s P/E(ttm) Range Over the Past 10 Years
Min: 13.66  Med: 22.24 Max: 58.61
Current: 53.28
13.66
58.61
PE(NRI) 53.28
BIO's PE(NRI) is ranked lower than
76% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.55 vs. BIO: 53.28 )
Ranked among companies with meaningful PE(NRI) only.
BIO' s PE(NRI) Range Over the Past 10 Years
Min: 13.66  Med: 22.47 Max: 58.61
Current: 53.28
13.66
58.61
Price/Owner Earnings (ttm) 124.74
BIO's Price/Owner Earnings (ttm) is ranked lower than
92% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.54 vs. BIO: 124.74 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.69  Med: 20.11 Max: 134.78
Current: 124.74
9.69
134.78
P/B 1.94
BIO's P/B is ranked higher than
77% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. BIO: 1.94 )
Ranked among companies with meaningful P/B only.
BIO' s P/B Range Over the Past 10 Years
Min: 1.45  Med: 1.81 Max: 3.02
Current: 1.94
1.45
3.02
P/S 2.53
BIO's P/S is ranked higher than
59% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. BIO: 2.53 )
Ranked among companies with meaningful P/S only.
BIO' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.57 Max: 2.55
Current: 2.53
0.87
2.55
PFCF 159.85
BIO's PFCF is ranked lower than
95% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.43 vs. BIO: 159.85 )
Ranked among companies with meaningful PFCF only.
BIO' s PFCF Range Over the Past 10 Years
Min: 9.61  Med: 24.99 Max: 469.08
Current: 159.85
9.61
469.08
POCF 33.43
BIO's POCF is ranked lower than
75% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.33 vs. BIO: 33.43 )
Ranked among companies with meaningful POCF only.
BIO' s POCF Range Over the Past 10 Years
Min: 7.48  Med: 13.05 Max: 45.73
Current: 33.43
7.48
45.73
EV-to-EBIT 33.13
BIO's EV-to-EBIT is ranked lower than
75% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.82 vs. BIO: 33.13 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.3 Max: 33.23
Current: 33.13
8.4
33.23
EV-to-EBITDA 16.70
BIO's EV-to-EBITDA is ranked higher than
51% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.42 vs. BIO: 16.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 9.1 Max: 16.75
Current: 16.7
6
16.75
Shiller P/E 38.77
BIO's Shiller P/E is ranked lower than
52% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.55 vs. BIO: 38.77 )
Ranked among companies with meaningful Shiller P/E only.
BIO' s Shiller P/E Range Over the Past 10 Years
Min: 19.56  Med: 27.64 Max: 42.78
Current: 38.77
19.56
42.78
Current Ratio 4.18
BIO's Current Ratio is ranked higher than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. BIO: 4.18 )
Ranked among companies with meaningful Current Ratio only.
BIO' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 3.11 Max: 4.52
Current: 4.18
1.87
4.52
Quick Ratio 2.92
BIO's Quick Ratio is ranked higher than
63% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. BIO: 2.92 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.38 Max: 3.45
Current: 2.92
1.22
3.45
Days Inventory 205.65
BIO's Days Inventory is ranked lower than
86% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 85.13 vs. BIO: 205.65 )
Ranked among companies with meaningful Days Inventory only.
BIO' s Days Inventory Range Over the Past 10 Years
Min: 151.29  Med: 169.37 Max: 205.65
Current: 205.65
151.29
205.65
Days Sales Outstanding 64.91
BIO's Days Sales Outstanding is ranked lower than
51% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.09 vs. BIO: 64.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.75 Max: 89.45
Current: 64.91
63.37
89.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BIO's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. BIO: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -1.1 Max: -0.2
Current: -1
-1.3
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.83
BIO's Price/Net Current Asset Value is ranked lower than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. BIO: 9.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.86  Med: 6.72 Max: 95.94
Current: 9.83
2.86
95.94
Price/Tangible Book 2.65
BIO's Price/Tangible Book is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.57 vs. BIO: 2.65 )
Ranked among companies with meaningful Price/Tangible Book only.
BIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 2.78 Max: 6.43
Current: 2.65
1.14
6.43
Price/Projected FCF 1.65
BIO's Price/Projected FCF is ranked higher than
64% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BIO: 1.65 )
Ranked among companies with meaningful Price/Projected FCF only.
BIO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.26 Max: 17.2
Current: 1.65
0.78
17.2
Price/Median PS Value 1.61
BIO's Price/Median PS Value is ranked lower than
85% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. BIO: 1.61 )
Ranked among companies with meaningful Price/Median PS Value only.
BIO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.89 Max: 1.62
Current: 1.61
0.23
1.62
Price/Graham Number 2.51
BIO's Price/Graham Number is ranked higher than
59% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. BIO: 2.51 )
Ranked among companies with meaningful Price/Graham Number only.
BIO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.69  Med: 1.66 Max: 4.42
Current: 2.51
0.69
4.42
Earnings Yield (Greenblatt) (%) 3.02
BIO's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.94 vs. BIO: 3.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.01  Med: 7.5 Max: 11.9
Current: 3.02
3.01
11.9
Forward Rate of Return (Yacktman) (%) -7.45
BIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.70 vs. BIO: -7.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -7.5  Med: 10.8 Max: 22.4
Current: -7.45
-7.5
22.4

More Statistics

Revenue (TTM) (Mil) $2,067
EPS (TTM) $ 3.33
Beta0.72
Short Percentage of Float6.13%
52-Week Range $122.03 - 174.85
Shares Outstanding (Mil)29.42
» More Articles for BIO

Headlines

Articles On GuruFocus.com
Mariko Gordon Invested in 5 Companies in 2nd Quarter Aug 21 2016 
Royce 100 Fund Shareholder Letter Sep 20 2015 
Widely Held Guru Stocks Near Historical Low P/B Ratios Aug 11 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 23 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 14 2014 

More From Other Websites
Hedge Funds Are Betting On Bio-Rad Laboratories, Inc. (BIO) Dec 01 2016
Microbiome MDx specialist Genetic Analysis and Bio-Rad Sign Agreement Nov 28 2016
Microbiome MDx specialist Genetic Analysis and Bio-Rad Sign Agreement Nov 28 2016
ETFs with exposure to Bio-Rad Laboratories, Inc. : November 16, 2016 Nov 16 2016
BIO RAD LABORATORIES INC Financials Nov 10 2016
ETF’s with exposure to Bio-Rad Laboratories, Inc. : November 4, 2016 Nov 04 2016
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
Bio-Rad Laboratories (BIO) Catches Eye: Stock Jumps 6.5% Nov 03 2016
BIO RAD LABORATORIES INC Files SEC form 10-Q, Quarterly Report Nov 02 2016
Edited Transcript of BIO earnings conference call or presentation 1-Nov-16 9:00pm GMT Nov 01 2016
Bio-Rad posts 3Q profit Nov 01 2016
Bio-Rad posts 3Q profit Nov 01 2016
Bio-Rad posts 3Q profit Nov 01 2016
BIO RAD LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 01 2016
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent Nov 01 2016
Q3 2016 Bio Rad Laboratories Inc Earnings Release - After Market Close Nov 01 2016
Medical Product Nov 1 Earnings Lineup: CERN, IDXX, DXCM, BIO Oct 31 2016
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : October... Oct 27 2016
Bio-Rad Introduces its IH-1000 Blood Typing System for the U.S. Market Oct 24 2016
Bio-Rad Introduces its IH-1000 Blood Typing System for the U.S. Market Oct 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)